NCT03185806

Brief Summary

The acute peripancreatic fluid collections (AFPCs) is the most common complication in severe acute pancreatitis (SAP). There are controversies on optimal timing for drainage of APFCs in SAP. The early-stage percutaneous catheter drainage (PCD) of sterile peripancreatic fluid collections is questioned as a result of the major cause of secondary infection. The aim of the present randomized controlled trial is to compare the outcomes in terms of mortality, secondary infection of peripancreatic collections, organ failure, length of hospital/ICU stay and inflammatory biomarkers between the early-stage PCD of sterile AFPCs and conservative therapy.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
100

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Oct 2017

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 30, 2017

Completed
15 days until next milestone

First Posted

Study publicly available on registry

June 14, 2017

Completed
4 months until next milestone

Study Start

First participant enrolled

October 6, 2017

Completed
3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 6, 2020

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 6, 2020

Completed
Last Updated

October 9, 2017

Status Verified

May 1, 2017

Enrollment Period

3 years

First QC Date

May 30, 2017

Last Update Submit

October 5, 2017

Conditions

Keywords

severe acute pancreatitissterile acute peripancreatic fluid collectionspercutaneous catheter drainage

Outcome Measures

Primary Outcomes (1)

  • Mortality

    Determine and compare the death rates in patients who are administered drainage and conservative therapy: Assess the total number of cases of death in each group (Treatment and control)

    From date of admisstion until the date of in-hospital death or death within two weeks after discharging, whichever came first, assessed up to 1 year.

Secondary Outcomes (6)

  • Secondary infection of peripancreatic collections

    From date of admisstion until the secondary infection of peripancreatic collections occurred, assessed up to 100 days

  • New set of organ failure

    From date of admisstion until new set of organ failure occurred, assessed up to 100 days

  • Length of hospital/ICU stay

    From date of admisstion until the patient is transfered to normal ward or discharge, whichever came first, assessed up to 1 year.

  • Aggressive procedures: open necrosectomy and minimally invasive retroperitoneal necrosectomy

    From date of admisstion until the patient receives aggressive procedures, assessed up to 100 days

  • Abdominal hemorrhage

    From date of admisstion until the abdominal hemorrhage occurred, assessed up to 100 days

  • +1 more secondary outcomes

Study Arms (2)

Puncture and Drainage

EXPERIMENTAL

The enrolled SAP patients are administered puncture and drainage use 8-F or 10-F pigtail tube under guidance of B ultrasound or CT scan.

Device: Puncture and drainage

Conservative therapy

NO INTERVENTION

The enrolled SAP patients are administered conservative therapy and without puncture and prolonged drainage.

Interventions

The enrolled SAP patients are punctured under guidance of B ultrasound or CT scan, and prolonged drained by 8-F or 10-F pigtail tube

Puncture and Drainage

Eligibility Criteria

Age18 Years - 70 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age of 18 years to 70 years; and
  • Pain characteristic of pancreatitis; and
  • Elevated serum lipase or amylase (≥3-fold upper normal range); and
  • Persistent organ failure \>48 hours; and
  • Organ dysfunction occurred within 7 days after onset of pain; and
  • Presentation with a width of ≥2cm of APFCs in the peripheral tissues of the pancreas, the cyst of lesser omentum , or the paracolic sulci on CT image.

You may not qualify if:

  • History diseases of chronic organ dysfunction; or
  • Traumatic pancreatitis; or
  • Post-endoscopic retrograde cholangiopancreatography(ERCP) pancreatitis; or
  • Severe coagulopathy (INR\>2); or
  • Severe thrombocytopenia (PLT≤50×109/L); or
  • No suitable route for puncturing; or
  • Pregnancy; or
  • Absent of informed consent from patient or representative.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

The second affiliated hospital of Zhejiang University

Hangzhou, Zhejiang, China

RECRUITING

MeSH Terms

Conditions

Pancreatitis

Interventions

Paracentesis

Condition Hierarchy (Ancestors)

Pancreatic DiseasesDigestive System Diseases

Intervention Hierarchy (Ancestors)

Specimen HandlingClinical Laboratory TechniquesDiagnostic Techniques and ProceduresDiagnosisDrainageTherapeuticsPuncturesSurgical Procedures, OperativeInvestigative Techniques

Central Study Contacts

Tingbo Liang, MD,PhD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 30, 2017

First Posted

June 14, 2017

Study Start

October 6, 2017

Primary Completion

October 6, 2020

Study Completion

October 6, 2020

Last Updated

October 9, 2017

Record last verified: 2017-05

Locations